m+Medelevator.RU
← Поиск публикаций
Advanced healthcare materials · 2026

Pandemic-Responsive Molecularly Imprinted Polymer-Based Electrochemical Sensor for Mpox Detection.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Seo Youngjun, Kim Yonghwan, Kim Jaeheung, Jang Jae Won, Jung Hyo Gi, Park Dongsung, Shin Yonghoon, Kim Hongrae, Kim Yeon Ho, Bang Junho, Kim Hyunji, Lee Jeong Hoon, Lee Dongtak, Hwang Kyo Seon, Yoon Dae Sung

Аннотация

In 2022, a global Mpox outbreak occurred, and the World Health Organization (WHO) declared it a Public Health Emergency of International Concern (PHEIC). Although the outbreak was quickly constrained, new cases of infection associated with mutated virions continue to be documented worldwide. In recent global health crises, there is an urgent need to develop rapid, cost-effective diagnostic assays. While nucleic acid assays (e.g., PCR and CRISPR-based methods) represent the current gold standard for Mpox virus (MPXV) detection, point-of-care (POC) assays for Mpox remain limited. Here, we developed a molecularly imprinted polymer (MIP)-based MPXV sensor targeting A29L, a surface protein involved in host cell binding. The MIP sensor exhibits a remarkable detection limit of 7.7 pg/mL (0.54 pM). Moreover, we demonstrated that the MIP sensor detected A29L in artificial interstitial fluid (AIF) with a detection limit of 12.4 pg/mL (0.86 pM), supporting sensitive detection in a lesion-relevant model matrix. The MIP sensor preferentially responded to A29L over MPXV B6R, vaccinia virus A27L, and biointerferents and retained its response after 30 days. The results indicate that the MIP-based MPXV sensor has strong potential for clinical Mpox detection and could serve as a valuable diagnostic platform in future pandemics.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты